- Home
- CYBN vs CGEN Comparison
CYBN vs CGEN Comparison
Compare CYBN & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYBN
- CGEN
- Stock Information
- Founded
- CYBN 2019
- CGEN 1993
- Country
- CYBN Canada
- CGEN Israel
- Employees
- CYBN N/A
- CGEN N/A
- Industry
- CYBN Pharmaceuticals and Biotechnology
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CYBN Health Care
- CGEN Health Care
- Exchange
- CYBN Nasdaq
- CGEN Nasdaq
- Market Cap
- CYBN 127.3M
- CGEN 117.8M
- IPO Year
- CYBN N/A
- CGEN 2000
- Fundamental
- Price
- CYBN $7.96
- CGEN $1.47
- Analyst Decision
- CYBN Strong Buy
- CGEN Strong Buy
- Analyst Count
- CYBN 4
- CGEN 1
- Target Price
- CYBN $86.00
- CGEN $4.00
- AVG Volume (30 Days)
- CYBN 326.6K
- CGEN 216.5K
- Earning Date
- CYBN 06-25-2025
- CGEN 05-19-2025
- Dividend Yield
- CYBN N/A
- CGEN N/A
- EPS Growth
- CYBN N/A
- CGEN N/A
- EPS
- CYBN N/A
- CGEN N/A
- Revenue
- CYBN N/A
- CGEN $27,589,000.00
- Revenue This Year
- CYBN N/A
- CGEN $11.81
- Revenue Next Year
- CYBN N/A
- CGEN $28.37
- P/E Ratio
- CYBN N/A
- CGEN N/A
- Revenue Growth
- CYBN N/A
- CGEN N/A
- 52 Week Low
- CYBN $4.81
- CGEN $1.13
- 52 Week High
- CYBN $13.88
- CGEN $2.66
- Technical
- Relative Strength Index (RSI)
- CYBN 61.23
- CGEN 53.98
- Support Level
- CYBN $7.00
- CGEN $1.38
- Resistance Level
- CYBN $8.50
- CGEN $1.56
- Average True Range (ATR)
- CYBN 0.53
- CGEN 0.08
- MACD
- CYBN 0.15
- CGEN 0.02
- Stochastic Oscillator
- CYBN 76.00
- CGEN 68.97
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.